Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have shown remarkable therapeutic efficacy against BRCA1/2 mutant cancers through a synthetic lethal interaction. PARPis are believed to exert their therapeutic effects mainly through the blockade of single-strand DNA damage repair, which leads to the accumulation of toxic DNA double strand breaks, specifically in cancer cells with DNA repair deficiency (BCRAness), including those harboring BRCA1/2 mutations.
Introduction
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of patients with ovarian and breast cancers harboring BRCA1 or BRCA2 (BRCA1/2) mutations (1, 2) . The rationale supporting the development of single agent PARP inhibitors (PARPis) in BRCA1/2 mutant cancers was based on the concept of synthetic lethality, which predicted antitumor efficacy in tumors with defects in homologous recombination (HR) repair, also known as BRCAness. PARP1 is the most abundant and ubiquitously expressed member of the PARP family and contributes the majority of PARP enzymatic activity and is thus the major target of PARPis (3) . In the presence of DNA damage, PARP1 rapidly binds to DNA strand breaks and is essential for the repair of DNA single-strand breaks (SSBs) through base excision repair. In normal cells, recombinogenic DNA substrates generated by PARPis can be functionally resolved by the error-free HR repair pathway. In contrast, in cancer cells with defective HR repair, such as those deficient in BRCA1 or BRCA2, the DNA substrates generated by PARPis cannot be resolved, and therefore the cells are hypersensitive to PARPis (4, 5) .
Clinical studies have now also shown patient benefit with PARPis in those with BRCA1/2 wildtype tumors (6) . A recent Phase III clinical trial confirmed that patients with platinum-sensitive, recurrent ovarian cancer receiving PARPi treatment as maintenance therapy had significantly longer progression-free survival than those on placebo, regardless of BRCA1/2 mutation status or HR repair status (7) . These clinical observations raise the key question of whether PARPis can exert antitumor effects through mechanisms other than those leading to unresolved genomic lesions in tumors with DNA repair deficiency.
In this study, we show that PARPi treatment induces IFN-mediated antitumor immune responses. PARPis generate cytosolic double-strand DNA (dsDNA), which activate STING signaling and its associated-transcription programs. These critical changes amplify STING signaling and promote tumor infiltrating lymphocytes (TILs) and antitumor immunity, which can be further enhanced through immune checkpoint blockade.
Materials and Methods
Cell culture. Cell lines were validated by short tandem repeat (STR) DNA fingerprinting using the AmpF STR identifier kit according to the manufacturer's instructions (Applied Biosystems, catalogue no. 4322288). The STR profiles were compared to known American Type Culture Collection fingerprints; to the Cell Line Dr. Vahid Afshar-Kharghan's laboratory at MD Anderson. The ID8 cells were maintained in DMEM (high-glucose, Cellgro) supplemented with 4% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 ng/ml sodium selenite. Cells were incubated at 37°C in a humidified incubator with 5%
CO2.
Antibodies and reagents. Anti-γH2AX (JBW301) antibodies were purchase from Millipore Sigma. Anti-β-Actin (A2228), anti-α-Tubulin (T6074) and anti-γ-Tubulin (SAB4503045) antibodies were purchase from Sigma-Aldrich. Anti-STING (D2P2F, #13647), anti-cGAS (D1D3G, #15102), anti-IRF3 (D6I4C, #11904), anti-phospho-IRF3 (Ser396, D6O1M, #29047), anti-TBK1 (D1B4, #3504), anti-phospho-TBK1 (Ser172, D52C2, #5483), anti-CtIP (D76F7, #9201), anti-MRE11 (#4895) and anti-PD-L1 (13684 and 64988) antibodies were purchased from Cell Signaling Technology. Anti-CD8 (sc-7970), anti-BLM (B-4, sc-365753), anti-EXO1 (SPM394, sc-56387) and other antibodies were purchased from Santa Cruz Biotechnology. BMN673 (S7048, Talazoparib) was purchased from Selleck Chemicals. VivoGlo Luciferin was purchased from Promega. Isotype control IgG and anti-PD-L1 (BE0101, clone 10F.9G2) antibodies were purchased from Bio X Cell. The ELISA kits of CCL5 and CXCL10 were purchase from Thermofisher. The multiplexed immunofluorescence IHC kit was purchased from PerkinElmer. and phospho-TBK1, immunofluorescent staining was performed essentially as described previously (8) . After treatment, cells were first fixed in ice-cold methanol for 10 min at -20°C, then blocked with 10% goat serum for 30 min at room Otherwise, unpaired t-tests were used to generate two-tailed P values.
Results

PARPi induces an accumulation of cytosolic DNA and activates STING signaling pathway
PARPi treatment markedly induced DNA double-strand breaks (DSBs) as detected by increased γ-H2AX levels, and thus caused cell cycle arrest in S phase ( Supplementary Fig. S1A and S1B) . The cytosolic DNA sensor cGAS is the most potent activator of the STING signaling pathway (9) . After the recognition of cytosolic DNA, cGAS activates STING via generation of 2'-5' cyclic GMP-AMP (cGAMP).
STING, in turn, induces phosphorylation and nuclear translocation of IFN
transcriptional regulatory factors TANK-binding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3) (10, 11) . We thus sought to determine whether PARPi induces accumulation of cytosolic DNA that could activate the cGAS-STING-TBK1-IRF3 axis in ovarian cancer cell lines HOC1 (BRCA1/2 WT), UPN251 (BRCA1 deleterious and restoration mutations, functional WT) (12) and HeLa (BRCA1/2 WT).
As indicated by staining with the dsDNA-specific dye PicoGreen, BMN673 caused a significant accumulation of cytosolic dsDNA in multiple cell lines (Fig. 1A) .
Moreover, phosphorylation of IRF3 and TBK1, two key components along the STING signaling pathway, was markedly elevated by BMN673 treatment in a timedependent manner in three different cancer cell lines (Fig. 1B) . Immunofluorescent staining also showed that PARPi remarkably induced the translocation of phospho-IRF3, phospho-TKB1, as well as total IRF3 and total TBK1 from the cytoplasm to the nucleus (Fig. 1C) , which indicated functional activation of STING signaling. We then examined mRNA expression of CCL5 and CXCL10, two major target genes downstream of STING activation that are involved in T-cell chemotaxis (13) . We found a time-dependent increase in CCL5 and CXCL10 mRNA levels after PARPi treatment (Fig. 1D) . Consistent with these changes in mRNA levels, PARPi substantially increased the production of CXCL10 as detected by ELISA (Fig. 1E) .
To determine if cGAS-STING-TBK1-IRF3 signaling is essential to the induction of chemokine expression by PARPi, we knocked down STING, TBK1, IRF3 or cGAS ( Supplementary Fig. S2A, S3A ) and treated cells with PARPi. We found significantly reduced upregulation of CCL5 and CXCL10 in response to PARPi treatment in these cells ( Fig. 1F and Supplementary Fig. S2B, S2C) . Together, these results demonstrate that PARPi induces accumulation of cytosolic dsDNA and activation of cGAS-STING-TBK1-IRF3 signaling to promote chemokine expression.
To identify the source of the cytosolic dsDNA induced by PARPi, we examined if factors involved in the degradation of DNA substrates at replication lesions might be required for the STING-dependent induction of immune response by PARPi. Several key factors containing and/or regulating nuclease activity, including MRE11, CtIP, BLM and EXO1, are recruited to DSBs, which can produce DNA fragments during HR repair and maintenance of replication fork stability (14) . We reasoned that trapping of PARP1 by PARPi forms a barrier against DSB end resection and HR repair, which may lead to generation of dsDNA through degradation of unrepaired reversed replication forks. Indeed, we demonstrated that knockdown of these resection factors by siRNAs markedly reduced mRNA expression of CXCL10 ( Fig.  1G and Supplementary Fig. S3B ), suggesting a key role for the requirement of these factors in generating PARPi-induced immune responses.
PARPi activates STING signaling and immune checkpoint in vivo
We next investigated the in vivo effects of PARPi-induced immune responses.
We used syngeneic immunocompetent mouse models of ovarian cancer (ID8) and colon cancer (CT26), which were treated with a clinically-relevant dosage of BMN673 (0.33 mg/kg). CT26 and ID8 cells have no known mutations in genes involved in the HR repair pathway, including BRCA1/2 mutations. As expected, PARPi treatment exhibited no therapeutic effects in the xenograft model with the intraperitoneal injection of ID8 cells ( Fig. 2A and 2B) . However, in the ID8 syngeneic model, PARPi can remarkably reduce tumor growth and significantly prolong survival ( Fig. 2C) . These data indicated that an intact T cell-mediated immune response is required for PARPi efficacy in the ID8 model.
It has been reported that expression levels of CCL5 and CXCL10 positively correlate with infiltrating CD8 + cytotoxic lymphocytes in various cancers (15, 16) . We thus conducted immunohistochemistry (IHC) analysis of STING activation and immune response. In syngeneic ID8 and CT26 models, PARPi significantly upregulated the levels of Sting and phospho-Irf3, indicating robust activation of the Sting signaling pathway in vivo ( Fig. 2D and Supplementary Fig. S4A ). Consistent with this finding, remarkably higher percentages of CD8 positivity, a key cytotoxic T lymphocyte marker (17) , as well as higher percentages of PD-L1 positivity, a marker of immune checkpoint activation, were found in PARPi-treated tumors than in control tumors in both models ( Fig. 2E and Supplementary Fig. S4B ).
Furthermore, we used ELISA and qPCR assays to validate functional activation of the Sting signaling pathway in animal models. As shown in Fig. 2F and 2G , PARPi treatment induced expression of Ccl5 and Cxcl10, which was consistent with in vitro studies (Fig. 1) . Together, these data showed that PARPi treatment induces an 
Immune checkpoint blockade targeting PD-1/PD-L1 pathway potentiates therapeutic efficacy of PARPi in syngeneic mouse models.
To test this possibility, we first treated mice with intraperitoneal ID8 tumors with control IgG, BMN673, anti-PD-L1, or the combination of BMN673 and anti-PD-L1 for 3 weeks and then stopped treatment and monitored tumor growth and mouse survival (Fig. 3A) . We found that only the combination treatment significantly reduced tumor growth compared to IgG control while no significant changes in mouse weight were observed ( Fig. 3B-3E) . Consistent with relatively poor immunogenicity and low tumor-infiltrating lymphocyte levels in ID8 tumors (18) , and the fact that the major role of the PD-1/PD-L1 immune checkpoint is to limit the activity of effector T cells in the tumor microenvironment, ID8 tumors did not significantly respond to anti-PD-L1 therapy after 3 weeks of treatment ( Fig. 3C-3E) .
BMN673 alone reduced tumor growth; however, the reduction did not achieve statistical significance (Fig. 3C-3E) . In the third week of treatment, mice developed ascites which interfered with further luciferase measurements, but the study was continued to measure survival. As shown in Fig. 3F , only the combination treatment significantly prolonged survival compared to the IgG control; treatment with singleagent BMN673 or anti-PD-L1 did not substantially alter survival. Continuous treatment with the combination of BMN673 and anti-PD-L1 produced a remarkably better outcome than treatment with this regimen for three weeks (Fig. 3G) , consistent with ongoing activity of the combination regimen. Notably, continuous treatment with the combination therapy led to long-term survival in 2 of the 10 mice (20%) bearing ID8 tumors ( Fig. 3G) , suggesting a potential curative effect from this continuous regimen.
We next used CT26 mouse colon tumor cells as an independent syngeneic model to validate the effects of combination therapy using BMN673 and anti-PD-L1.
Because CT26 tumors grew aggressively, mice were treated for 12 days before the tumor size reached the maximum volume allowed by the animal protocol. Consistent with our observations in the ovarian cancer model, the combination therapy significantly reduced tumor burden compared to IgG control (Fig. 3H) . However, these tumors were not sensitive to BMN673 alone. Collectively, these results indicated that the combination of BMN673 and anti-PD-L1 significantly inhibits tumor growth and prolongs survival in syngeneic cancer models.
The therapeutic effects of combining PARPi and anti-PD-L1 depend on an intact immune system.
To further confirm that the synergistic effects of the combination of BMN673 and anti-PD-L1 are dependent on an immune response, mouse xenografts of ID8 and CT26 were generated in nude mice, which do not contain a competent adaptive immune system. None of the treatments examined -BMN673 monotherapy, anti-PD-L1 monotherapy, and the combination of BMN673 and anti-PD-L1 -inhibited tumor growth or improved survival ( Fig. 4A-4D) . These results strongly supported the notion that an intact immune system is a prerequisite to achieve the benefits of combination therapy.
Discussion
Here we show PARPi leads to an accumulation of cytosolic dsDNA and thereby activates the cGAS-STING-TBK1-IRF3 innate immune pathway, which upregulates transcriptional programs to produce type I IFN and its related immune responses (Fig. 4E) . Using two syngeneic mouse models with inherently less immunogenic tumors, we demonstrate that PARPi treatment enhances tumor susceptibility to immune checkpoint blockade. Importantly, these responses were observed regardless of the BRCA1/2 mutation status of the cell lines assessed both in vitro and in vivo.
Recent studies have shown that micronuclei resulting from mis-segregation of DNA during cell division can be recognized by the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) and activate the stimulator of interferon (IFN) genes (STING) innate immune pathway (19) . However, it remains unknown whether PARPi-induced DNA damage is sufficient to generate cytosolic DNA that may serve as a signaling molecule to prime an immune response through the activation of the STING pathway. Our data showed that DNA damage induced by PARPi generates cytosolic DNA, primarily dsDNA, which functions as an immune stimulus engaging activation of the STING pathway. A recent study showed that ionizing radiation (IR) induces primarily cytosolic ssDNA (20) . The different forms of cytosolic DNA resulting from DNA damage may depend on the mechanisms by which cells cope with DNA damage. In the presence of IR-induced DSB, DSB end resection is initiated for HR repair. ssDNA can be generated by nucleases that control DNA end resection including BLM and EXO1 (14) . However, PARPis induces stalled or collapsed replication forks. dsDNA generated by PARPi may be related to DNA replication fork degradation/reversion or the restart of replication. Our study thus proposes a novel molecular mechanism underlying PARPi therapeutic effects, which is independent of its conventional cytotoxic effects resulting from unresolved DNA damage in DNA repair-deficient cancer cells.
Since the immunogenic responses induced by PARPi is not dependent on DNA repair deficiency, our findings may explain the antitumor activity observed in PARPi treated patients regardless of BRCA1/2 mutation status or the presence of HR defective genomic signature (7) . Our study also suggests that PARPi in combination with immune checkpoint inhibitors may demonstrate benefit in tumors regardless of DNA repair status, which has important clinical implications. Indeed, multiple Phase Ib combination trials, including BMN673 and the PD-L1 inhibitor avelumab are currently ongoing in the clinic. The results from the studies herein provide important information on mechanisms of sensitivity, as well as a route to potential biomarkers of efficacy. 
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